

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



SoftMedx Healthcare Limited

京玖醫療健康有限公司

(Incorporated in Hong Kong with limited liability)

(Stock Code: 648)

UPDATE ON RESUMPTION AND TERMINATION OF LOAN CAPITALISATION

This announcement is made by the Company pursuant to Rule 13.24A of the Listing Rules and reference is made to the announcements of the Company dated 30 April and 13 June 2024. Capitalised terms used in this announcement shall adopt the same meaning as those defined in the said announcements.

UPDATE ON RESUMPTION PROGRESS

On 21 April 2020, the Stock Exchange informed the Company that it would withhold exercising its right to delist the Company under Rule 6.01A(2)(b)(i) of the Listing Rules pending further development of the Company's submission to the Commission and may exercise its right under Rule 6.01A of the Listing Rules at a later stage when it considers appropriate. The Company will continue to take steps to address the concerns of the Commission and the Stock Exchange.

UPDATE ON BUSINESS OPERATION AND TERMINATION OF LOAN CAPITALISATION

The Group is principally engaged in the healthcare business for distribution of medical equipment and products in Hong Kong involving dental equipment and products and its business operation is continuing as usual in all material aspects. On 31 July 2024, the Company and the Subscriber entered into a deed to terminate the Loan Capitalisation Agreement and extend the maturity date of the Subscriber Loan to 31 March 2025. As of the date of this announcement, the Scheme has been successfully implemented and cash distribution had been made to the scheme creditors whose claims had been admitted by the scheme administrator. The Board will continue to monitor the impact of trading suspension on the operational and financial performance of the Group and take appropriate measures and publish announcements where appropriate.

GENERAL

Trading in the shares of the Company will continue to be suspended pending fulfilment of the resumption conditions. Shareholders and potential investors of the Company should exercise caution when dealing in the shares of the Company.

For and on behalf of the board of
SoftMedx Healthcare Limited
Lam Sung Him Gaston
Company Secretary

Hong Kong, 31 July 2024

As at the date of this announcement, the board of directors of the Company comprises Mr. Cheung Wai Kwan and Mr. Wang Jianguo as executive directors; and Ms. Hu Xuezheng, Mr. Lin Pinzhao and Mr. Yiu Chun Wing as independent non-executive directors.